P Martin1, A Chadburn2, P Christos3, R Furman1, J Ruan1, M A Joyce1, E Fusco1, P Glynn1, R Elstrom1, R Niesvizky1, E J Feldman1, T B Shore1, M W Schuster1, S Ely2, D M Knowles2, S Chen-Kiang2, M Coleman1, J P Leonard4. 1. Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital. 2. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College. 3. Division of Biostatistics and Epidemiology, Department of Public Health, Weill Cornell Medical College and New York Presbyterian Hospital, New York, USA. 4. Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital. Electronic address: jpleonar@med.cornell.edu.
Abstract
BACKGROUND: Reported median overall survival (OS) in patients with mantle cell lymphoma (MCL) has been reported to be just 3-4 years. As a consequence, first-line treatment has become more aggressive. Single-center studies with R-Hyper-CVAD and/or autologous stem-cell transplant (ASCT) have produced 3-year OS rates >80%, prompting many to adopt their use. We evaluated outcomes from a single-center cohort managed in a more traditional fashion. METHODS: We identified patients with MCL evaluated at Weill Cornell Medical Center since 1997, and included those with known date of diagnosis. An online social security database was used to verify survival. RESULTS: We identified 181 patients with MCL, and date of diagnosis could be determined in 111. Three-year OS from diagnosis was 86% [95% confidence interval (CI) 78% to 92%]. Median OS was 7.1 years (95% CI 63-98 months). Adequate information on therapy was available for 75 patients. Only five were treated upfront with (R)-Hyper-CVAD or ASCT while an additional four patients received one of these regimens subsequently. Treatment type had no significant effect on OS. CONCLUSION: Outcomes with standard approaches can yield similar survival to that achieved with more intensive approaches. Biases may account for the perceived superiority of aggressive strategies.
BACKGROUND: Reported median overall survival (OS) in patients with mantle cell lymphoma (MCL) has been reported to be just 3-4 years. As a consequence, first-line treatment has become more aggressive. Single-center studies with R-Hyper-CVAD and/or autologous stem-cell transplant (ASCT) have produced 3-year OS rates >80%, prompting many to adopt their use. We evaluated outcomes from a single-center cohort managed in a more traditional fashion. METHODS: We identified patients with MCL evaluated at Weill Cornell Medical Center since 1997, and included those with known date of diagnosis. An online social security database was used to verify survival. RESULTS: We identified 181 patients with MCL, and date of diagnosis could be determined in 111. Three-year OS from diagnosis was 86% [95% confidence interval (CI) 78% to 92%]. Median OS was 7.1 years (95% CI 63-98 months). Adequate information on therapy was available for 75 patients. Only five were treated upfront with (R)-Hyper-CVAD or ASCT while an additional four patients received one of these regimens subsequently. Treatment type had no significant effect on OS. CONCLUSION: Outcomes with standard approaches can yield similar survival to that achieved with more intensive approaches. Biases may account for the perceived superiority of aggressive strategies.
Authors: John Gerecitano; Carol Portlock; Paul Hamlin; Craig H Moskowitz; Ariela Noy; David Straus; Philip Schulman; Otilia Dumitrescu; Debra Sarasohn; Jennifer Pappanicholaou; Alexia Iasonos; Zhigang Zhang; Qianxing Mo; Endri Horanlli; Celeste N Rojas; Andrew D Zelenetz; Owen A O'Connor Journal: Clin Cancer Res Date: 2011-02-23 Impact factor: 12.531
Authors: Vaishalee P Kenkre; Walter L Long; Jens C Eickhoff; Jules H Blank; Thomas A McFarland; Wayne Bottner; Hamied Rezazedeh; Jae E Werndli; Howard H Bailey; Brad S Kahl Journal: Leuk Lymphoma Date: 2011-09
Authors: Julie E Chang; Christopher Peterson; Sangbum Choi; Jens C Eickhoff; KyungMann Kim; David T Yang; Leslie A Gilbert; Eric S Rogers; Jae E Werndli; Michael S Huie; Thomas A McFarland; Michael Volk; Jules Blank; Natalie S Callander; Walter L Longo; Brad S Kahl Journal: Br J Haematol Date: 2011-08-16 Impact factor: 6.998
Authors: Timothy S Fenske; Mei-Jie Zhang; Jeanette Carreras; Ernesto Ayala; Linda J Burns; Amanda Cashen; Luciano J Costa; César O Freytes; Robert P Gale; Mehdi Hamadani; Leona A Holmberg; David J Inwards; Hillard M Lazarus; Richard T Maziarz; Reinhold Munker; Miguel-Angel Perales; David A Rizzieri; Harry C Schouten; Sonali M Smith; Edmund K Waller; Baldeep M Wirk; Ginna G Laport; David G Maloney; Silvia Montoto; Parameswaran N Hari Journal: J Clin Oncol Date: 2013-12-16 Impact factor: 44.544